These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 10464822

  • 1. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children.
    Barnes NC, Thwaites RM, Price MJ.
    Respir Med; 1999 Jun; 93(6):402-7. PubMed ID: 10464822
    [Abstract] [Full Text] [Related]

  • 2. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma.
    Stempel DA, Stanford RH, Thwaites R, Price MJ.
    Clin Ther; 2000 Dec; 22(12):1562-74. PubMed ID: 11192147
    [Abstract] [Full Text] [Related]

  • 3. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
    Lyseng-Williamson KA, Plosker GL.
    Pharmacoeconomics; 2003 Dec; 21(13):951-89. PubMed ID: 12959627
    [Abstract] [Full Text] [Related]

  • 4. [The effect of cost evaluation in the treatment of asthma].
    Sorli J.
    Med Arh; 1999 Dec; 53(3 Suppl 1):15-7. PubMed ID: 10546462
    [Abstract] [Full Text] [Related]

  • 5. Inhaled salmeterol/fluticasone propionate combination. A pharmacoeconomic review of its use in the management of asthma.
    Markham A, Adkins JC.
    Pharmacoeconomics; 2000 Dec; 18(6):591-608. PubMed ID: 11227397
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group.
    Lundbäck B, Jenkins C, Price MJ, Thwaites RM.
    Respir Med; 2000 Jul; 94(7):724-32. PubMed ID: 10926346
    [Abstract] [Full Text] [Related]

  • 7. [Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part I. Mechanisms of actions and clinical effectiveness of treatment in children with asthma].
    Bartkowiak-Emeryk M, Breborowicz A, Emeryk A, Kulus M, Kurzawa R, Lis G, Mazurek H, Niedziela M.
    Pol Merkur Lekarski; 2004 Jul; 17 Suppl 2():5-10. PubMed ID: 15688663
    [Abstract] [Full Text] [Related]

  • 8. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R.
    Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.
    Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, Pauwels RA, Weiss KB.
    J Allergy Clin Immunol; 2003 Dec; 112(6):1229-36. PubMed ID: 14657888
    [Abstract] [Full Text] [Related]

  • 10. Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.
    Lamb HM, Culy CR, Faulds D.
    Pharmacoeconomics; 2000 Nov; 18(5):487-510. PubMed ID: 11151402
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis.
    Ståhl E, van Rompay W, Wang EC, Thomson DM.
    Ann Allergy Asthma Immunol; 2000 Apr; 84(4):397-402. PubMed ID: 10795647
    [Abstract] [Full Text] [Related]

  • 12. Asthma: the role of fluticasone propionate.
    Br J Hosp Med; 1997 Dec 10; 58(11):555-64. PubMed ID: 10193470
    [Abstract] [Full Text] [Related]

  • 13. Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate.
    Rojas RA, Paluga I, Goldfrad CH, Duggan MT, Barnes N.
    J Asthma; 2007 Dec 10; 44(6):437-41. PubMed ID: 17654129
    [Abstract] [Full Text] [Related]

  • 14. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
    Baumgarten C, Geldszus R, Behre U, Peslis N, Trautmann M, Viani-Initial Study Group.
    Eur J Med Res; 2002 Jan 29; 7(1):1-7. PubMed ID: 11827834
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice.
    Andersson F, Kjellman M, Forsberg G, Möller C, Arheden L.
    Ann Allergy Asthma Immunol; 2001 May 29; 86(5):537-44. PubMed ID: 11379805
    [Abstract] [Full Text] [Related]

  • 16. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma.
    Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C.
    J Pediatr; 2005 Aug 29; 147(2):213-20. PubMed ID: 16126052
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma.
    Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED.
    Respir Med; 2006 Apr 29; 100(4):586-94. PubMed ID: 16274980
    [Abstract] [Full Text] [Related]

  • 18. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
    Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K.
    Ann Allergy Asthma Immunol; 2004 May 29; 92(5):523-9. PubMed ID: 15191020
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study.
    Weiss K, Buxton M, Andersson FL, Lamm CJ, Liljas B, Sullivan SD.
    Pediatr Allergy Immunol; 2006 May 29; 17 Suppl 17():21-7. PubMed ID: 16573705
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.